Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib maintenance after standard chemoradiotherapy for IDH-mutant astrocytoma
NL-OMON59119Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vorasidenib in astrocytoma, sponsored by European Organisation for Research and Treatment of Cancer. Started Jan 2026; status: recruiting.
02
Drugs
vorasidenib
03
Conditions
astrocytoma
Beyond the preview
Go deeper on NL-OMON59119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59119.